The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

Innovation, collaboration, and regulatory reform were on the agenda at the 2025 Clinical Trial Supply Europe conference.

Key Innovations and 5 Companies to Watch in 2025Artificial intelligence is everywhere in 2024, changing industries and ...

California allowed college athletes to earn money, profiting off their name, image and likeness. University records show ...

Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...

The S&P 500 dropped 2.7% on Monday, March 10, as U.S. tariffs and government job cuts heightened economic uncertainty and ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and ...

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...

Recent refinements to a multiphase approach to delusional infestations make this treatment protocol effective even within a ...